Ken Griffin’s Enlivex Therapeutics ENLV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-70,136
| Closed | -$68K | – | 6118 |
|
|
2025
Q1 | $68K | Buy |
+70,136
| New | +$68K | ﹤0.01% | 5278 |
|
|
2024
Q4 | – | Hold |
0
| – | – | – | 6177 |
|
|
2024
Q3 | – | Hold |
0
| – | – | – | 6004 |
|
|
2024
Q2 | – | Sell |
-55,525
| Closed | -$210K | – | 6135 |
|
|
2024
Q1 | $210K | Buy |
55,525
+48,439
| +684% | +$184K | ﹤0.01% | 4737 |
|
|
2023
Q4 | $19.1K | Sell |
7,086
-30,597
| -81% | -$82.6K | ﹤0.01% | 5386 |
|
|
2023
Q3 | $59.5K | Sell |
37,683
-932
| -2% | -$1.47K | ﹤0.01% | 5016 |
|
|
2023
Q2 | $102K | Sell |
38,615
-10,849
| -22% | -$28.5K | ﹤0.01% | 4744 |
|
|
2023
Q1 | $180K | Sell |
49,464
-10,068
| -17% | -$36.6K | ﹤0.01% | 4669 |
|
|
2022
Q4 | $232K | Buy |
59,532
+19,978
| +51% | +$77.9K | ﹤0.01% | 4555 |
|
|
2022
Q3 | $168K | Buy |
+39,554
| New | +$168K | ﹤0.01% | 4926 |
|
|
2022
Q2 | – | Hold |
0
| – | – | – | 6231 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 6538 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 6617 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 6540 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 6553 |
|
|
2021
Q1 | – | Sell |
-10,823
| Closed | -$91K | – | 6371 |
|
|
2020
Q4 | $91K | Buy |
+10,823
| New | +$91K | ﹤0.01% | 4713 |
|
|
2017
Q2 | – | Sell |
-570
| Closed | -$17K | – | 3768 |
|
|
2017
Q1 | $17K | Buy |
+570
| New | +$17K | ﹤0.01% | 3551 |
|
|
2016
Q4 | – | Sell |
-279
| Closed | -$19K | – | 3694 |
|
|
2016
Q3 | $19K | Buy |
+279
| New | +$19K | ﹤0.01% | 3442 |
|